Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Explore wealth mindset tips and strategies that can help you build wealth smartly. Start applying these techniques for success!
28,655 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Savers are rethinking cash holdings as rates rise. Here are three higher-yield alternatives traditional savings that ...
A couple with $4.2 million in retirement assets faces a $200,000 request from their 32-year-old daughter to fund a do...
Nasdaq’s Bitcoin options approval marks a regulatory milestone, paving the way for QBTC to trade inside the US option...
ScrollPay Technologies is redefining mobile monetization by paying users for screen time. Deloitte’s fastest-growing ...
A handful of the nation’s most fervent sports markets chose not to bid for hosting World Cup games in 2026, citing fi...
A new risk is emerging in loans: AI-powered data moves faster than traditional checks can validate. Banks are redesig...
Bitcoin is moving beyond ETFs into a new class of financial primitives, powering insurance reserves, margin for trade...
A veteran market analyst argues that military drones, not consumer EVs, may drive the next leap in battery technology...
AI-driven data centers are fueling a power supercycle, pushing on-site generation and turbocharging turbine prices. G...
AVUV has climbed this year, but rate expectations and bank exposure keep its outlook uncertain. Here’s what AVUV inve...
A Paris court setback keeps the ownership fight over the Miraval winery alive as investors weigh the financial stake ...